NCT02735941 is a clinical trial in Ulcerative Colitis, sponsored by Medical University of Graz.

Who is sponsoring NCT02735941?

NCT02735941 is sponsored by Medical University of Graz.

What condition does NCT02735941 study?

NCT02735941 studies Ulcerative Colitis, Crohn's Disease, Colon Cancer.

Is NCT02735941 still recruiting?

NCT02735941 is currently completed. Last updated 30 July 2018.

Last reviewed 2018-07-30 · How we verify

NCT02735941

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases

Completed Last updated 30 July 2018

What this trial tests

trial in Ulcerative Colitis in 31 participants. Completed in 27 July 2018.

Timeline

13 June 2017

Primary endpoint
27 July 2018

27 July 2018

Quick facts

Lead sponsor	Medical University of Graz
Status	Completed
Study type	OBSERVATIONAL
Enrollment	31
Start date	13 June 2017
Primary completion	27 July 2018
Estimated completion	27 July 2018
Sites	1 location across Austria

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →
Crohn's Disease — all drugs for Crohn's Disease →
Colon Cancer — all drugs for Colon Cancer →

Sponsor

Medical University of Graz

Who can join

18 and older, any sex, with Ulcerative Colitis or Crohn's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to investigate phospholipid ligands and their receptors in inflammatory bowel diseases and colon cancer. Several new species of lipids have been recently discovered which are able to transmit information to cancer cells in the large intestine. The lipids and their responsive receptors build an axis that is thought to influence the development of inflammation and cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cannabinoids in the landscape of cancer.
Mangal N, Erridge S, Habib N, Sadanandam A, et al · · 2021 · cited 72× · PMID 34259916 · DOI 10.1007/s00432-021-03710-7
Natural compounds as safe therapeutic options for ulcerative colitis.
Gupta M, Mishra V, Gulati M, Kapoor B, et al · · 2022 · cited 55× · PMID 35212849 · DOI 10.1007/s10787-022-00931-1
Natural approaches for the management of ulcerative colitis: evidence of preclinical and clinical investigations.
Subudhi RN, Poonia N, Singh D, Arora V. · · 2024 · cited 14× · PMID 39078427 · DOI 10.1007/s13659-024-00463-x

Verify or expand the search:

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02735941 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 30 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02735941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing